13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • DIV-SCLC-301

    Acronym: 

    DISTINCT

    ACTRN/NCT /ethics: 

    Scientific title: 

    A Two-Part, open-Label, Randomized, Phase II/III Study of Dinutuximab and irinotecan versus Irinotecan for second line treatment of subjects with relapsed or refractory small cell lung cancer

    Summary of trial and patient characteristics

    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase II, Phase III Tumour Stream Small Cell Lung Cancer
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase II, Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Small Cell Lung Cancer
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A Two-Part, open-Label, Randomized, Phase II/III Study of Dinutuximab and irinotecan versus Irinotecan for second line treatment of subjects with relapsed or refractory small cell lung cancer

    Lay Summary

    A Two-Part, open-Label, Randomized, Phase II/III Study of Dinutuximab and irinotecan versus Irinotecan for second line treatment of subjects with relapsed or refractory small cell lung cancer

    Sponsor / Cooperative group

    United Therapeutics

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Nimit Singhal Recruiting
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting